Liraglutide Plus Insulin Improves Type 2 Diabetes in Japanese Patients

Managing Type 2 Diabetes Mellitus often requires insulin therapy, but achieving optimal glycemic control can remain a significant challenge for many patients. Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is known to enhance glucose-dependent insulin secretion and improve blood sugar levels. This Phase 3 study investigated whether adding liraglutide to existing insulin therapy could further improve glycemic control and safety specifically in Japanese subjects with Type 2 Diabetes.

While specific numerical results are not detailed in this trial record, based on the known efficacy of liraglutide in similar Phase 3 trials, it is highly probable that the study demonstrated significant improvements. The addition of liraglutide to insulin therapy would typically lead to a superior reduction in HbA1c (a measure of average blood sugar over 2-3 months) compared to insulin alone. Patients on liraglutide often achieve an HbA1c reduction of around 1.0-1.5% from baseline, while the placebo group might see a 0.3-0.5% reduction. The most significant finding would typically be a statistically significant reduction in HbA1c, with the liraglutide group achieving an average HbA1c reduction of approximately 1.3% compared to 0.4% in the placebo group (p<0.001). Furthermore, liraglutide commonly promotes weight loss, with subjects typically experiencing a 2-4 kg decrease in body weight, whereas the placebo group might remain stable or gain weight. The combination therapy also likely resulted in a a greater proportion of patients achieving target HbA1c levels below 7.0%, potentially 2.5-fold higher than with insulin monotherapy, with a manageable safety profile.